HONG LEONG ASIA Reports Total Revenue of SGD 2075.1M For Q2 2023, a 1.0% Decrease YoY
August 19, 2023
🌥️Earnings Overview
For the quarter ended June 30, 2023, HONG LEONG ASIA ($SGX:H22) registered total revenue of SGD 2075.1 million, representing a 1.0% dip from the corresponding period of the previous year. Net income for the period amounted to SGD 30.8 million, a decrease of 27.8% compared to the same quarter last year.
Analysis
According to the Risk Rating, HONG LEONG ASIA is a medium risk investment in terms of financial and business aspects. GoodWhale has detected 2 risk warnings in the income sheet and balance sheet. Investors should be aware of these risk warnings before making any investments. To find out more about these risk warnings, register on goodwhale.com. GoodWhale not only provides an analysis of the financials, but also provides insights on different aspects of the company such as the management team, corporate governance, and capital structure. With the help of GoodWhale, investors can gain a better understanding of the company and its operations before making any investments. Therefore, it is a great tool to help investors make informed decisions and maximize their returns. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for H22. More…
| Total Revenues | Net Income | Net Margin |
| 3.86k | 42.75 | 1.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for H22. More…
| Operations | Investing | Financing |
| 3.57 | -109.97 | 144.19 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for H22. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 5.65k | 3.32k | 1.19 |
Key Ratios Snapshot
Some of the financial key ratios for H22 are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -2.7% | -19.6% | 4.4% |
| FCF Margin | ROE | ROA |
| -3.0% | 11.8% | 1.9% |
Peers
In the market for commercial vehicles, Hong Leong Asia Ltd faces competition from Anhui Ankai Automobile Co Ltd, Touyun Biotech Group Ltd, and Li Bao Ge Group Ltd. These companies are all vying for a share of the market with their own unique offerings. Hong Leong Asia Ltd has been able to maintain its position as a leading manufacturer through its focus on quality and innovation.
– Anhui Ankai Automobile Co Ltd ($SZSE:000868)
Anhui Ankai Automobile Co Ltd is a Chinese manufacturer of buses and coaches. It is headquartered in Hefei, Anhui Province, and has a market cap of 4.88B as of 2022. The company’s ROE is -90.93%.
– Touyun Biotech Group Ltd ($SEHK:01332)
Touyun Biotech Group Ltd is a company that focuses on the research and development of biotechnology. The company’s market cap as of 2022 is 1.22B, and its ROE is -15.83%. Touyun Biotech Group Ltd’s main products are medical devices and equipment, pharmaceuticals, and health supplements. The company is headquartered in Beijing, China.
– Li Bao Ge Group Ltd ($SEHK:01869)
Li Bao Ge Group Ltd is a Chinese company with a market cap of 295M as of 2022. The company’s primary business is the manufacture and sale of construction materials. The company’s ROE is 118.91%.
Summary
HONG LEONG ASIA reported total revenue of SGD 2075.1 million for the second quarter ended June 30, 2023, a slight decrease of 1.0% year-on-year. Net income also decreased by 27.8% to SGD 30.8 million compared to the same period last year. Despite these results, the company’s stock price moved higher on the day, suggesting investors still have faith in its prospects. The company’s long-term performance should be monitored closely for insights into whether it can continue to deliver strong returns for shareholders.
Related Posts
Recent Posts
